Stockreport

Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency

Mustang Bio, Inc.  (MBIO) 
Last mustang bio, inc. earnings: 11/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: mustangbio.com/investor-relations
PDF MB-107 preceded by low-dose busulfan conditioning continues to be well tolerated and results in development of functional immune system in newly diagnosed infants with X [Read more]